Drugs / eutidrone
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT05781633 | Jul 2022 → Jul 2023 | breast cancer | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | eutidrone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05781633 ↗ |
| Route | Intravenous | “eutidrone(30mg/m2/d,iv,d1-5,21d/cycle)” NCT05781633 ↗ |